| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Elie Azoulay | Q42222310 |
| P2093 | author name string | Virginie Lemiale | |
| Sandra Assoun | |||
| P2860 | cites work | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis | Q26785746 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Cetuximab for the treatment of colorectal cancer. | Q27851419 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Combined vemurafenib and cobimetinib in BRAF-mutated melanoma | Q27853076 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network | Q28485085 | ||
| Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports | Q28553328 | ||
| Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 | ||
| Ipilimumab as a Cause of Severe Pan-Colitis and Colonic Perforation | Q42255119 | ||
| Erratum: Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. | Q42407939 | ||
| Ipilimumab-induced perforating colitis | Q43532238 | ||
| Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. | Q46232500 | ||
| Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma | Q46329140 | ||
| Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma | Q46796397 | ||
| Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. | Q48507831 | ||
| Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma. | Q54367805 | ||
| Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Q56679480 | ||
| Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis | Q56888890 | ||
| Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab - case report | Q56897082 | ||
| Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy | Q58024768 | ||
| Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer | Q86902269 | ||
| Liver transplantation treating the patient with hepatic failure associated with sorafenib treatment: report of a case | Q87233533 | ||
| Severe inflammatory ileitis resulting in ileal perforation in association with combination immune checkpoint blockade for metastatic malignant melanoma | Q88286896 | ||
| Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q89148986 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
| Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 | ||
| Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck | Q29619277 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer | Q29620676 | ||
| Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
| Improved survival with bevacizumab in advanced cervical cancer | Q33566222 | ||
| A phase 3 trial of bevacizumab in ovarian cancer | Q34030022 | ||
| Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy). | Q34232474 | ||
| Everolimus for advanced pancreatic neuroendocrine tumors. | Q34399809 | ||
| Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. | Q34444495 | ||
| Combination immunotherapy: a road map. | Q34552128 | ||
| Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study | Q34614776 | ||
| Review: side effects of approved molecular targeted therapies in solid cancers. | Q34731665 | ||
| Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil | Q34935734 | ||
| Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy | Q35965389 | ||
| Fulminant Myocarditis with Combination Immune Checkpoint Blockade | Q37595462 | ||
| Management of immune-related adverse events and kinetics of response with ipilimumab | Q38012057 | ||
| Molecular-targeted agents combination therapy for cancer: developments and potentials | Q38104670 | ||
| Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study | Q38245038 | ||
| Survival in solid cancer patients following intensive care unit admission. | Q38249876 | ||
| A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. | Q38427448 | ||
| Management of toxicities of immune checkpoint inhibitors. | Q38732543 | ||
| Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. | Q38752269 | ||
| Managing Adverse Events With Immune Checkpoint Agents | Q38816844 | ||
| Immune checkpoint inhibitors in challenging populations | Q38939708 | ||
| Cardiovascular Toxic Effects of Targeted Cancer Therapies | Q38978969 | ||
| Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy | Q39311439 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 988-997 | |
| P577 | publication date | 2019-05-29 | |
| P1433 | published in | Intensive Care Medicine | Q15749164 |
| P1476 | title | Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases | |
| P478 | volume | 45 |
Search more.